Abstract
Coronary artery disease (CAD) is a type of heart disease with high incidence and mortality in Europe and the United States as well as in Asian countries. miRNA is a kind of regulatory RNA which controls gene expression by binding to complementary sequences of their targets, thus promotes RNA degradation and/or inhibits protein translation. Recent studies showed miRNAs function as key mediators in the pathological process of CAD which supply potential targets for CAD treatment. Expression of several miRNAs is heart-specific and CAD-specific, in addition to the signature that miRNAs are stable in plasma and other body fluids, makes miRNAs potential biomarkers for CAD diagnosis, therapeutic efficacy and prognosis. Here, the review will summarize the development of miRNAs involved in CAD.
Keywords: biomarker, coronary heart disease, diagnosis, miRNA, prognosis.
Current Signal Transduction Therapy
Title:Role of miRNAs in Coronary Artery Disease
Volume: 9 Issue: 3
Author(s): Leixing Xie, Ruikai Du, Jingxue Niu and Hongbin Liu
Affiliation:
Keywords: biomarker, coronary heart disease, diagnosis, miRNA, prognosis.
Abstract: Coronary artery disease (CAD) is a type of heart disease with high incidence and mortality in Europe and the United States as well as in Asian countries. miRNA is a kind of regulatory RNA which controls gene expression by binding to complementary sequences of their targets, thus promotes RNA degradation and/or inhibits protein translation. Recent studies showed miRNAs function as key mediators in the pathological process of CAD which supply potential targets for CAD treatment. Expression of several miRNAs is heart-specific and CAD-specific, in addition to the signature that miRNAs are stable in plasma and other body fluids, makes miRNAs potential biomarkers for CAD diagnosis, therapeutic efficacy and prognosis. Here, the review will summarize the development of miRNAs involved in CAD.
Export Options
About this article
Cite this article as:
Xie Leixing, Du Ruikai, Niu Jingxue and Liu Hongbin, Role of miRNAs in Coronary Artery Disease, Current Signal Transduction Therapy 2014; 9 (3) . https://dx.doi.org/10.2174/1574362410666141224210818
DOI https://dx.doi.org/10.2174/1574362410666141224210818 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelin-1 and Human Platelets
Current Vascular Pharmacology Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Obesity and Inflammation – Targets for OA Therapy
Current Drug Targets Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Getting to the Heart of the Matter: Exploring Opportunities for Gene Therapy Treatment of Dystrophic Cardiomyopathy
Current Gene Therapy Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry Nanodiagnostic Attainments and Clinical Perspectives on C-Reactive Protein: Cardiovascular Disease Risks Assessment
Current Medicinal Chemistry Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Box-Behnken Optimized Methodology for the Quantification of Diclofenac using a Carbon Paste-Multiwalled Carbon Nanotubes Electrode
Current Analytical Chemistry Hypertension in Egypt: A Systematic Review
Current Hypertension Reviews Metabolic Syndrome and Asthma
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi: A Sulfated Glycoprotein Antigen as Relevant Candidate for Vaccine Development and Drug Target. A Review
Current Medicinal Chemistry Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety